Horizon Pharma PLC

Most Recent

  • uploads///biochemistry biology blue
    Company & Industry Overviews

    Horizon Therapeutics or BioMarin: Which Is a Better Bet in July?

    Horizon Therapeutics (HZNP) is up 23.13%, and BioMarin (BMRN) is down 6.62% year-to-date. Let’s study the drivers and risks for both these rare disease players in greater detail.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Analysts Raise Target Price for Horizon Pharma in March

    Wall Street analysts expect an upside potential of 11.65% for Horizon Pharma (HZNP) based on the company’s closing price on March 25.

    By Margaret Patrick
  • uploads///Shire
    Company & Industry Overviews

    Why Shire Stock Rose in the Week Ended March 29

    On March 29, 2018, Shire (SHPG) was trading at $149.39, which represented a 21% rise from its 52-week low of $123.73.

    By Daniel Collins
  • uploads///VRX revenue
    Company & Industry Overviews

    A Deeper Look at Valeant Pharmaceuticals’ Recent Financial Performance

    In 3Q16, Valeant Pharmaceuticals (VRX) generated revenues of $2.4 billion, compared with $2.2 billion in 3Q17.

    By Kenneth Smith
  • uploads///VRX divestments
    Company & Industry Overviews

    Inside Valeant Pharmaceuticals’ Recent Divestments

    Valeant Pharmaceuticals (VRX) was granted the worldwide exclusive licensing rights for manufacturing and selling the EyeGate 2 delivery system.

    By Kenneth Smith
  • uploads///VRX analysts reco
    Company & Industry Overviews

    Valeant Pharmaceuticals on the Street: Analyst Ratings This February

    Of the seven analysts covering Valeant Pharmaceuticals in February 2018, two analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///Jazz analyst
    Company & Industry Overviews

    How Analysts Rated Jazz Pharmaceuticals in December

    In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Jazz Pharmaceuticals on the Street: Analysts’ Recommendations after 1H17

    In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

    By Daniel Collins
  • uploads///Strensiq Revenues
    Company & Industry Overviews

    Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017

    In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.

    By Daniel Collins
  • uploads///anr
    Company & Industry Overviews

    What Are Analysts Saying about Horizon Pharma?

    According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”

    By Jillian Dabney
  • uploads///krystexxa
    Company & Industry Overviews

    Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug

    Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.

    By Jillian Dabney
  • uploads///Rayos
    Company & Industry Overviews

    Gauging the Performance of Horizon Pharma’s Rayos in 3Q16

    During the third quarter of 2016, Rayos, a delayed-release prednisone, rose 15.0% to $13.4 million compared to 3Q15.

    By Jillian Dabney
  • uploads///segments
    Company & Industry Overviews

    How Did Horizon Pharma Perform in 3Q16?

    In 3Q16, Horizon Pharma’s (HZNP) net sales on a GAAP basis fell to $208.7 million. Non-GAAP net sales were $273.7 million.

    By Jillian Dabney
  • uploads///drug portfolio
    Company & Industry Overviews

    Factors behind Horizon Pharma’s Volatility in December

    With the Express Scripts agreement, Horizon Pharma’s net sales in 2017 are expected to rise. The probability of a top-line expansion has boosted investor sentiment.

    By Jillian Dabney
  • uploads///Actimmune trials
    Company & Industry Overviews

    Horizon Pharma’s Steep Fall in December: What Happened?

    On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Why Neurocrine Biosciences May See Higher Losses in 2016

    Wall Street analysts have projected that Neurocrine Biosciences’ net income in 2016 will be -$146.2 million, a significantly higher loss than in 2015.

    By Margaret Patrick
  • uploads///Procysbi
    Company & Industry Overviews

    Procysbi: Major Addition to Horizon’s Orphan Drug Portfolio

    According to Horizon Pharma’s (HZNP) estimates, Procysbi holds a peak sales potential of more than $300 million.

    By Jillian Dabney
  • uploads///horizon as orphan drug company
    Company & Industry Overviews

    Buy Allows Horizon to Further Expand into Orphan Drug Space

    Through the acquisition of Raptor Pharmaceuticals, Horizon Pharma (HZNP) will gain access to Procysbi and Quinsair and expand in the orphan drug space.

    By Jillian Dabney
  • uploads///deal benefits
    Company & Industry Overviews

    News of Acquisition Caused Horizon Pharma Stock to Rise

    The market was pleased with the merger deal between Horizon Pharma (HZNP) and Raptor Pharmaceuticals. HZNP shares rose to $18.89 on September 12.

    By Jillian Dabney
  • uploads///deal details
    Company & Industry Overviews

    How the Numbers Add Up for the Horizon Pharma–Raptor Deal

    According to the September 12, 2016, agreement between Horizon Pharma (HZNP) and Raptor Pharmaceuticals, HZNP will acquire Raptor common stock at $9 per share.

    By Jillian Dabney
  • uploads///Rheumatology
    Company & Industry Overviews

    Understanding the Growth Drivers behind Horizon’s Rheumatology Business Unit

    Horizon Pharma’s Rheumatology portfolio includes Rayos, or Lodotra, and Krystexxa. Rayos is indicated for rheumatoid arthritis, PMR, and Lupus.

    By Jillian Dabney
  • uploads///Primary care sales
    Company & Industry Overviews

    What Are the Prospects for Horizon’s Primary Care Segment?

    Horizon Pharma’s Primary Care division is the company’s largest revenue contributor and grew by 33% on a yearly basis in 2Q16.

    By Jillian Dabney
  • uploads///diversified sales
    Company & Industry Overviews

    Inside Horizon’s Orphan and Rheumatology Business Unit

    Multiple acquisitions have helped Horizon expand its portfolio into orphan drugs and rheumatology. Now it has a total of nine drugs under its umbrella.

    By Jillian Dabney
  • uploads/// Sales estimates
    Company & Industry Overviews

    What’s Really Driving Horizon’s Valuation?

    In 1Q16, Horizon Pharm’s sales on a YoY basis grew by 81% to $205 million. During that period, its adjusted EBITDA jumped annually by 122% to $72 million.

    By Jillian Dabney
  • uploads///ev to ebitda
    Company & Industry Overviews

    The Truth behind Horizon’s EV-to-EBITDA Performance

    On June 29, 2016, Horizon Pharma was trading at a forward EV-to-EBITDA multiple of 4.67x, which is at a discount when compared with peers.

    By Jillian Dabney
  • uploads///Graph
    Company & Industry Overviews

    Positive Top-Line Data May Help Secure FDA Approval for Valbenazine

    Neurocrine Biosciences has seen positive results from Kinect 3, a phase-3 trial that tested the efficacy and safety of Valbenazine for tardive dyskinesia.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside Neurocrine Biosciences’ Analyst Recommendations in 2016

    Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

    By Margaret Patrick
  • uploads///nitropress and isuprel
    Company & Industry Overviews

    The Facts behind the Valeant Drug Pricing Controversy

    Valeant Pharmaceuticals International (VRX) significantly raised the prices of two of its heart drugs—Nitropress and Isuprel—which caused a controversy and an outrage.

    By Jillian Dabney
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap Stock Update: Horizon Tanks 21% on Earnings Concerns

    In the mid-cap space, Horizon Pharma (HZNP) was the worst hit, falling by 21% for the week ended April 15, 2016.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Mid-Cap News: Intercept Rose on Accelerated Approval of Ocaliva

    Intercept Pharmaceuticals (ICPT) rose 19.6% for the week ended April 8, 2016. It closed at $156.36 and was trading above its 20-day and 100-day moving averages

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    Anacor Pharmaceuticals: $250 Million in Convertible Senior Notes

    Anacor Pharmaceuticals rose 7.8% and closed at $61.51 on April 4, 2016. It was trading above its 20-day moving average. Year-to-date, the stock has fallen 45.6%.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Neurocrine Biosciences’ Valbenazine Launch: What You Need to Know

    Neurocrine Biosciences (NBIX) expects to submit a new drug application to the FDA for Valbenazine in 2016.

    By Margaret Patrick
  • uploads///Krystexxa
    Company & Industry Overviews

    Introducing Krystexxa, the Latest Addition to Horizon’s Orphan Portfolio

    In January 2016, Horizon acquired Krystexxa from Crealta Holdings. The drug has been approved by the FDA for the treatment of chronic refractory gout.

    By Jillian Dabney
  • uploads///Actimmune
    Company & Industry Overviews

    Why Actimmune, Horizon’s Lead Orphan Product, Has Such Huge Potential

    After the Vidara merger in September 2014, Horizon Pharma gained access to Actimmune, which has been approved by the FDA for CGD and SMO.

    By Jillian Dabney
  • uploads///Primary care sales
    Company & Industry Overviews

    Inside the Performance of Horizon’s Primary Care Division

    In fiscal 4Q15, Horizon’s Primary Care sales rose by more than 125%. The growth of the division was primarily driven by volume rather than by price.

    By Jillian Dabney
  • uploads///acquisitions
    Company & Industry Overviews

    How Horizon Became a Growth Stock

    Over the past 18 months, Horizon Pharma has acquired three orphan drugs. The acquisition of Hyperion Therapeutics in May 2015 gave it Ravicti and Buphenyl.

    By Jillian Dabney
  • uploads///Price to sales
    Company & Industry Overviews

    Why Is Horizon Trading at a Premium on a Price-to-Sales Basis?

    On March 24, Horizon Pharma was trading at a forward PS multiple of 2.18x. It appears to be trading at a premium next to Valeant, Mallinckrodt, and Endo.

    By Jillian Dabney
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    IBB Leads Biotech ETFs with Rise of 3.1%

    Markets rose in the week ended November 20, as many believed the FED will hike the interest rate in December. The iShares Nasdaq Biotechnology ETF (IBB) rose 3.1%.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Horizon Rose and Outperformed IBB’s Mid-Cap Stocks

    Horizon Pharma rose 5.4% on November 16, 2015. The stock rose due to the update at the shareholder meeting regarding the Depomed acquisition.

    By Peter Neil
  • uploads///Graph Part  Nov
    Earnings Report

    ISIS Leads the Mid-Cap Space, Stock Rises by 12.3%

    ISIS Pharmaceuticals rose by 12.3% as it announced 3Q15 earnings. ISIS reported revenue of $49.1 million as compared to $44.1 million in 3Q14.

    By Peter Neil
  • uploads///bebcebeeaae
    Company & Industry Overviews

    More QE, Cheaper Euro Will Benefit Investors in European Equity

    European equity was rising, even outperforming major developed markets, in the first half of 2015. But the Greece debt crisis and China’s stock market crash pulled back the surge.

    By Surbhi Jain
  • uploads///Graph Part
    Company & Industry Overviews

    IBB Remained Flat Last Week

    The iShares Nasdaq Biotechnology ETF (IBB) gained marginally by 0.57% in the week ending September 18, 2015.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB ADRs Outperform Benchmark for August 10–17, 2015

    The iShares NASDAQ Biotechnology ETF (IBB) has 14 American Depository Receipts (ADR) in its portfolio. These ADRs have a weight of 9.36% and gave an average return of 0.85% for August 10–17, 2015.

    By Peter Neil
  • uploads///Part  Graph
    Company & Industry Overviews

    IBB’s American Depository Receipts Underperformed

    The iShares Nasdaq Biotechnology ETF (IBB) has 14 ADRs in its portfolio with a weight of 9.36%. Although XBI provides exposure to ADRs, it’s very limited.

    By Peter Neil
  • uploads///Part  Graph
    Earnings Report

    Horizon Pharma’s Specialty Business Unit in 2Q15

    As per a company press release, Horizon Pharma’s (HZNP) specialty business unit consists of two products: RAYOS and Lodotra.

    By Peter Neil
  • uploads///Part  Graph
    Earnings Report

    Horizon Pharma Appears to Be on an Acquisition Spree

    Horizon Pharma (HZNP), after acquiring Vidara Therapeutics on September 19, 2014, completed its second acquisition of Hyperion Therapeutics (HPTX) on May 7, 2015.

    By Peter Neil
  • uploads///Part
    Company & Industry Overviews

    Biotech ETF Provides Exposure to International Stocks

    The iShares Nasdaq Biotechnology ETF (IBB) has exposure to 14 international stocks, with a weight of 9.36%. For the week ended July 24, the average return of these shares was -2.13%.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.